18F-PSMA-1007 PET/CT 准确揭示的非区域淋巴结转移对转移性激素敏感性前列腺癌临床管理的影响
该回顾性研究纳入224例初诊转移性激素敏感性前列腺癌患者,分析18F-PSMA-1007 PET/CT与传统影像在揭示非区域淋巴结转移的一致性及其对管理的影响,发现两者一致性仅61.62%,PET/CT额外检出39.4%传统影像阴性的非区域淋巴结阳性患者,非区域淋巴结转移与更差的无进展生存相关。
要点
- 18F-PSMA-1007 PET/CT与传统影像揭示非区域淋巴结转移的一致性仅61.62%,Cohen kappa系数低至0.092。
- PET/CT额外检出37/94(39.4%)传统影像阴性的非区域淋巴结阳性患者。
- 低体积病合并非区域淋巴结转移患者中位PFS 19.5个月,短于无转移者27.5个月(P=0.01)。
核心结论
- 非区域淋巴结转移可被18F-PSMA-1007 PET/CT准确揭示,应被视为高体积特征,尤其合并骨转移时。
- 低体积病合并非区域淋巴结转移的患者可能适合更强化治疗,如早期多西他赛化疗。
研究设计与样本
- 回顾性分析224例初诊转移性激素敏感性前列腺癌患者的病历资料,其中101例(45.1%)仅接受传统影像进行TNM分期,24例(10.7%)仅接受18F-PSMA-1007 PET/CT,99例(44.2%)同时接受两者。
- 在初始治疗前同时接受18F-PSMA-1007 PET/CT与传统影像的患者中分析两者一致性。
- 高体积病定义为基于18F-PSMA-1007 PET/CT和/或传统影像发现的内脏转移和/或≥4处骨转移(≥1处位于椎体或骨盆之外)。
- 主要终点为无进展生存(PFS),采用Cox回归分析探索PFS的独立预测因素。
主要发现
- 99例同时接受18F-PSMA-1007 PET/CT与传统影像的患者中,两者揭示非区域淋巴结转移的一致性率仅61.62%,Cohen kappa系数低至0.092。
- 18F-PSMA-1007 PET/CT额外检出37/94(39.4%)传统影像阴性的非区域淋巴结阳性患者。
- 在224例患者中,Cox回归显示雄激素剥夺治疗(ADT)、N1、高体积病、非区域淋巴结转移和内脏转移与更差PFS相关(均P<0.05)。
- 在低体积病患者中,非区域淋巴结转移患者的中位PFS显著短于无转移患者(19.5 vs. 27.5个月,P=0.01)。
- 低体积病合并非区域淋巴结转移患者与高体积病患者的中位PFS差异无统计学意义(19.5 vs. 16.9个月,P=0.55)。
关键数值与推荐
- 非区域淋巴结转移一致性率61.62%,Cohen kappa系数0.092。
- PET/CT额外检出非区域淋巴结阳性37/94(39.4%)。
- 低体积病伴非区域淋巴结转移中位PFS 19.5个月 vs. 无转移27.5个月(P=0.01)。
- 低体积病伴非区域淋巴结转移中位PFS 19.5个月 vs. 高体积病16.9个月(P=0.55)。
- 早期多西他赛化疗较单用ADT显著延长PFS(20.7 vs. 12.3个月,P=0.008)。
临床怎么用
- 作者认为非区域淋巴结转移应被视为高体积特征,尤其合并骨转移时。
- 作者认为低体积病合并非区域淋巴结转移的患者可能适合更强化治疗,如早期多西他赛化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-regional lymph node (NRLN) metastases has shown increasing importance in the prognosis evaluation and clinical management of primary metastatic hormone-sensitive prostate cancer (mHSPC). Hence, this study aimed to investigate the concordance rates between 18F-PSMA-1007 PET/CT and conventional imaging (CI) in revealing NRLN metastases, and explore the impact of NRLN metastases on the management of primary mHSPC. METHODS: The medical records of 224 patients with primary mHSPC were retrospectively reviewed, including 101 patients (45.1%) only received CI for TNM classification, 24 patients (10.7%) only received 18F-PSMA-1007 PET/CT, and 99 patients (44.2%) received both 18F-PSMA-1007 PET/CT and CI. Among patients who received 18F-PSMA-1007 PET/CT and CI before initial treatment, the concordance rates between 18F-PSMA-1007 PET/CT and CI were analyzed. The high-volume disease was defined as the presence of visceral metastases and/or ≥ 4 bone metastases (≥ 1 beyond the vertebral bodies or the pelvis) based on the findings of 18F-PSMA-1007 PET/CT and/or CI. The primary endpoint was progression-free survival (PFS), and Cox regression analyses were performed to explore independent predictors of PFS. RESULTS: A total of 99 patients (44.2%) received both 18F-PSMA-1007 PET/CT and CI, the concordance rate in revealing NRLN metastases between 18F-PSMA-1007 PET/CT and CI was only 61.62%, and Cohen's kappa coefficient was as low as 0.092. Moreover, 18F-PSMA-1007 PET/CT detected an additional 37 of 94 (39.4%) patients with positive NRLNs who were negative on CI. Cox regression revealed that androgen deprivation therapy (ADT), N1, high-volume, NRLN and visceral metastases were associated with worse PFS (all P < 0.05) in 224 patients. Furthermore, in patients with low-volume disease, the median PFS of patients with NRLN metastases was significantly shorter than that of patients without NRLN metastases (19.5 vs. 27.5 months, P = 0.01), while the difference between patients with low-volume plus NRLN metastases and high-volume disease was not significant (19.5 vs. 16.9 months, P = 0.55). Moreover, early docetaxel chemotherapy significantly prolonged the PFS of these patients compared with ADT alone (20.7 vs. 12.3 months, P = 0.008). CONCLUSION: NRLN metastases could be accurately revealed by 18F-PSMA-1007 PET/CT, which should be considered a high-volume feature, especially concomitant with bone metastases. Furthermore, patients with low-volume plus NRLN metastases may be suitable for more intensive treatment, such as early docetaxel chemotherapy.
引用
- Jiang Z, Fan J, Gan C, et al. Impact of non-regional lymph node metastases accurately revealed on 18F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer. EJNMMI Res. 2023. PMID: 37410264. doi:10.1186/s13550-023-01009-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。